Moderna works on the development of a joint vaccine against influenza and COVID, it would be ready in 2023


At the same time, Moderna is preparing to publish data on the Omicron vaccine in March.


The executive president of the American pharmaceutical company Moderna, Stephane Bancel, pointed out this Monday at the Davos Forum that his The company continues to work on the development of a vaccine that works against the flu and also COVID-19, although it indicated that it will not be ready before the end of 2023.

“Our goal is to have a single annual booster dose so that people avoid having to get vaccinated two or three times in the winter,” Bancel explained.

Moderna’s vaccine is based on the COVID-19 virus before it mutated into different variants. Bancel indicated that the company is working on a specific compound against Ómicron that could be ready for trials in the coming weeks.

“We hope to be able to deliver data to regulators in March so we can determine next steps,” he said.

Laboratories are also in the race to come up with a vaccine that works against all mutations of the virus, both current and future.

Fourth dose is partially effective against Omicron variant, according to Israeli study

The fourth dose of the BioNTech/Pfizer and Moderna COVID-19 vaccine is only partially effective with the Omicron variant, According to the preliminary results of a study at the Sheba Medical Center in Israel, the research leader announced.

“Despite increased antibody levels, the fourth vaccine offers only partial defense against the virus. A) Yes, vaccines, which were more effective against earlier variants, offer less protection against Omicron”, Gili Regev-Yochay, who is leading the investigation, announced today.

The trial was conducted among 154 Sheba medical staff who received a BioNTech/Pfizer dose and 120 others who were inoculated with the Moderna dose.

All volunteers were previously vaccinated with the three doses of BioNTech/Pfizer.

“The trials showed that one week after people received the Moderna vaccine, the increase in antibody levels was similar to that of those who received Pfizer’s fourth vaccine,” concludes this first trial.

Furthermore, the research showed that two weeks after receiving the fourth BioNTech/Pfizer vaccine, “antibody levels continued to rise slightly after the first week.”

(With information from DW)

Read more:
COVID: Infections in Los Angeles County have increased 10 times in a month
Mexico resists the fourth wave of COVID and its variants
COVID: why Ómicron is having a more serious effect in the US than in Europe and South Africa

Comments are closed.